• Font Size:
  • Print

Miriam Metzinger submits: Stocks discussed in the lightning round session of Jim Cramer’s Mad Money TV program, Friday, August 3. Click on a stock ticker for more analysis:

Bullish calls:

Raytheon (RTN): 'Raytheon's probably the cheapest.'
General Dynamics (GD
Northrop Grumman (NOC)
Lockheed Martin (LMT)
Frontline (FRO):'Yours is a winner. Frontline is a buy. I see the stock went down today, but, you know, a lot of stocks went down today. That's a good one.'
UnitedHealth (UNH): 'Understand, I've owned this stock for a couple of years for my charitable trust. This is precisely the kind of stock that does well on a slowdown. ... I want to buy the stock.'
Norfolk Southern (NSC): 'Every railroad stock has been killed. ... All of them are owned by very big hedge funds. ... People say to themselves, 'I guess all the hedge funds are getting killed.' That is not true. ... I still like the stock.'
Trinity Industries (TRN): 'When this mortgage mess clears up, I think Trinity comes back. I think that's the kind of stock you buy. ... I'm not backing away."'
Nastech Pharmaceutical (NSTK): 'I would prefer, if you want to speculate, that you speculate with Nastech Pharmaceutical.'
American Standard (ASD): 'I frankly don't know why the market hates it so much. ... I'm stickin' by. It's painful, but I'm stickin' by it.'
LKQ (LKQX): 'I like your company. I would stick with it.'
Yamana Gold (AUY): 'I'll stick with Yamana.'

Bearish calls:

Boston Scientific (BSX): 'They canceled an IPO. I don't like the balance sheet. This is not my favorite company in the group. Even at $13, I'm going to reiterate that I can't get behind the medical company Boston Scientific.'
Spartan Motors (SPAR)
Jones Soda (JSDA): 'They missed the quarter. You cannot miss the quarter and be a high-multiple stock. Not only did they miss the quarter -- they missed the last quarter. ... I cannot pull the trigger. ... Jones is in the penalty box.'
Limited Brands (LTD): 'Here's a company that's doing absolutely everything right, but no one cares. My take is this: The Limited is too cheap, but I can't think of a catalyst to turn this stock around.'
St. Joe (JOE): 'I cannot be in the stock. It's just not the place to be.'
WCI Communities (WCI)
SuperGen (SUPG)
Coeur d'Alene Mines (CDE): 'I have never been a fan of Coeur d'Alene. They always issue a lot of stock. They never seem to go anywhere.'

Seeking Alpha publishes a summary of Jim Cramer's stock picks every day including: Mad Money Recap, Lightning Round, Stop Trading and Wall Street Confidential

Get Cramer's Picks by email -- it's free and takes only a few seconds to sign up.

Seeking Alpha is not affiliated with CNBC, Jim Cramer or TheStreet.com

SA Editor
Miriam Metzinger

About this author:
Become a Contributor Submit an Article

This article has 3 comments:

  •  
    Aug 06 10:30 AM
    Aug.6th,2007 Cramer touts NSTK for the 19th time but who's counting!
    Yea buy it before Wednesday's dismal earnings report.
    You want a good chance of speculation with a company that boasts a better statistics page than NSTK, then buy VPHM. It will do far better in next 10months than nstk.
    Overpriced stock nstk compared to sales!
    Other companies are doing well in phase trials with obesity and nstk is just what Cramer says"HOPE"
    All I know is I HOPE you purchase something else because nstk is not what it appears to be in my opinion!
  •  
    Aug 07 06:04 AM
    I suggest jim look at usse. This is really going to be a good one. jdc
  •  
    Aug 08 10:15 AM
    August 8th
    The stock has moved way too much on RNAi hype and very early pre-clinical and Phase I data for big targets such as obesity. They just raised a lot of money, hit the stock price, and they are going to have to do it again in a
    year or so at the rate they are burning money. The company will have to
    strike a major deal to see a major upside move in the stock. A
    marketing deal, that is -- big Pharma does not buy drug delivery companies.
    I believe fund managers are taking advantage of 19 Touts by Cramer then
    will short the stock and cash in Big time. Maybe not a conspiracy but shareholders are left in the dust all the time!
    Their statistics page is a disaster and they have to jump many hurdles with RNAI with FDA, Good Luck, you get what you pay for. NO PRODUCTS!

ETFs In Focus

  • Long Ideas

  • Short Ideas

  • Cramer's Picks